Sandusky, OH, October 20, 2021 (GLOBE NEWSWIRE) – PAO Group, Inc. (OTC Pink: PAOG) today revealed that the company is working on developing CBD products for pets and may have its first product ready. to be launched before the end of the year.
The market for pet products is estimated to be over $ 100 billion per year.
Last year, the company acquired intellectual property derived from research on CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). PAOG develops both pharmaceutical and nutraceutical treatments for humans based on this intellectual property. Today, for the first time, the company revealed that it is also developing CBD products for pets.
On Monday of this week, PAOG announced the launch of its first CBD nutraceutical product, RelaxRX CBD, a sleeping pill.
The company plans to launch its second CBD nutraceutical product on Thursday, October 21 this week.st, 2021.
PAOG is on track to achieve its first revenue this year, starting in the fourth quarter of 2021, since acquiring the extraction technology.
PAOG has confirmed the shipment of its first and second CBD nutraceuticals to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). The product will soon be on sale online at www.USMJ.com
PAOG expects revenue to grow rapidly after its first and second CBD nutraceutical product launches, as the company has tracked products lined up to track those products, increasing overall sales potential.
Learn more on the USMJ e-commerce site at www.usmj.com.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements contained in this press release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to to the safe harbor created by these rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding the future plans and potential objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the rapid implementation of any strategically important plan described above. The Company assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.